Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.41 |
| ▸ | RAB9A | P51151 | 4/20 | 0.41 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 3/20 | 0.38 |
| ▸ | CTSS | P25774 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | MMP2 | P08253 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 2/20 | 0.37 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | SLC1A3 | P43003 | 2/20 | 0.36 |
| ▸ | SLC1A2 | P43004 | 2/20 | 0.36 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.36 |
| ▸ | CTSK | P43235 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27388901 | 1.00 | NPC1 (0.41) | NPC1RAB9AADAMTS4MMP13CTSL | |
| SCHEMBL7445421 | 0.85 | NPC1 (0.39) | NPC1RAB9AADAMTS4MMP13CTSL | |
| SCHEMBL27547818 | 0.84 | NPC1 (0.44) | NPC1RAB9AADAMTS4MMP13ALDH1A1 | |
| SCHEMBL724209 | 0.82 | ALDH1A1 (0.50) | NPC1RAB9AADAMTS4MMP13CTSL | |
| SCHEMBL27507457 | 0.81 | NPC1 (0.44) | NPC1RAB9AALDH1A1SLC1A3SLC1A2 | |
| SCHEMBL9416878 | 0.81 | NPC1 (0.44) | NPC1RAB9AALDH1A1SLC1A3SLC1A2 | |
| Acetonitrile SCHEMBL27489701 | 0.81 | CTSS (0.42) | NPC1RAB9AADAMTS4MMP13CTSL | |
| SCHEMBL28581036 | 0.81 | MME (0.49) | NPC1RAB9AADAMTS4MMP13CTSL | |
| SCHEMBL27694402 | 0.78 | ALDH1A1 (0.47) | ALDH1A1PPARGPPARAMEN1KMT2A | |
| SCHEMBL27363772 | 0.78 | TSHR (0.30) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7825238-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2010-11-02 | — | — | US | disclosed |
| US-7071173-B2 | Antiviral methods employing double esters of 2′, 3′-dideoxy-3′-fluoroguanosine | MEDIVIR AB (SE) | 2006-07-04 | — | — | US | disclosed |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | MEDIVIR AB (SE) | 2006-06-08 | — | — | US | disclosed |
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | MEDIVIR AB (SE) | 2006-03-16 | — | — | US | disclosed |
| US-6974802-B2 | Treatment of viral infections using prodrugs of 2′,3-dideoxy,3′-fluoroguanosine | MEDIVIR AB (SE) | 2005-12-13 | — | — | US | disclosed |
| US-20030186924-A1 | Prodrugs | MEDIVIR AB | 2003-10-02 | — | — | US | disclosed |
| US-6458772-B1 | Prodrugs | MEDIVIR AB (SE) | 2002-10-01 | — | — | US | disclosed |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | AB, Medivir (SE) | 2002-09-12 | — | — | US | disclosed |
| EP-0721449-B1 | INHIBITORS OF BETA-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMA INC (US) | 2001-12-19 | — | — | EP | disclosed |
| EP-1150956-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2001-11-07 | — | — | EP | disclosed |
| US-6218568-B1 | REACTING 1-ARALKYLOXY-3-HALO-2-PROPANOL WITH METHOXYMETHYL ALKANOATE IN APROTIC SOLVENT IN THE PRESENCE OF A CATALYST TO PRODUCE 1-ARALKYLOXY-3-HALO-2-(ALKANOYLOXY)METHOXYPROPANE AND TREATING THE PRODUCT WITH ALKALI METAL ALKANOATE | SYNTEX (U.S.A.) INC. | 2001-04-17 | — | — | US | disclosed |
| US-6215017-B1 | 1-ARALKYLOXY-3-ACYLOXY-2-(ACYLOXY)METHOXYPROPANE DERIVATIVE; CHEMICAL INTERMEDIATES FOR VIRICIDE GANCICLOVIR | SYNTEX (U.S.A.) INC. | 2001-04-10 | — | — | US | disclosed |
| WO-2000047561-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | MEDIVIR AB (SE) | 2000-08-17 | — | — | WO | disclosed |
| US-6040446-A | Process for preparing a 2-(2-amino-1,6-dihydro-6-oxo-purin-9-yl) methoxy-1,3-propanediol derivative | SYNTEX (U.S.A.) INC. (US) | 2000-03-21 | — | — | US | disclosed |
| US-6034238-A | ANTIINFLAMMATORY AGENTS; ANTIARTHRITIC AGENT | HOECHST MARION ROUSSEL DEUTSCHLAND GMBH (DE) | 2000-03-07 | — | — | US | disclosed |
| US-5977074-A | THERAPY FOR ALZHEIMER'S DISEASE | MERRELL PHARMACEUTICALS, INC. (US) | 1999-11-02 | — | — | US | disclosed |
| WO-1997006178-A1 | PYRIMIDINE NUCLEOSIDES | F. HOFFMANN-LA ROCHE AG (CH) | 1997-02-20 | — | — | WO | disclosed |
| EP-0721449-A1 | INHIBITORS OF $g(b)-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMACEUTICALS INC. (US) | 1996-07-17 | — | — | EP | disclosed |
| WO-1995009838-A1 | INHIBITORS OF β-AMYLOID PROTEIN PRODUCTION | MERRELL PHARMACEUTICALS INC. (US) | 1995-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058259-A1 | ANTIVIRAL METHODS EMPLOYING DOUBLE ESTERS OF 2', 3'-DIDEOXY-3'-FLUOROGUANOSINE | UNG, HAVCR2, EIF2AK2 | NPC1 220/4885RAB9A 1697/4885ADAMTS4 2288/4885 |
| US-20030186924-A1 | Prodrugs | HAVCR2, CYP7A1, IGSF11 | NPC1 24/4885RAB9A 1881/4885ADAMTS4 2118/4885 |
| US-20060122383-A1 | Antiviral methods employing double esters of 2', 3'-dideoxy-3'-fluoroguanosine | UNG, HAVCR2, EIF2AK2 | NPC1 220/4885RAB9A 1697/4885ADAMTS4 2288/4885 |
| US-20020128301-A1 | Non-nucleoside reverse transcriptase inhibitors | SUB1, CBR1, GAR1 | NPC1 645/4885RAB9A 4637/4885ADAMTS4 4866/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.